BNR

Burning Rock Biotech

6.58 USD
+0.43
6.99%
At close Dec 20, 4:00 PM EST
1 day
6.99%
5 days
-1.79%
1 month
41.81%
3 months
103.72%
6 months
-3.24%
Year to date
-32.09%
1 year
-12.27%
5 years
-97.33%
10 years
-97.33%
 

About: Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Employees: 786

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 18 [Q2] → 18 (+0) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.03% less ownership

Funds ownership: 2.52% [Q2] → 2.49% (-0.03%) [Q3]

50% less capital invested

Capital invested by funds: $13.3M [Q2] → $6.69M (-$6.59M) [Q3]

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

Research analyst outlook

We haven’t received any recent analyst ratings for BNR.

Financial journalist opinion

Neutral
GlobeNewsWire
2 weeks ago
Burning Rock Reports Third Quarter 2024 Financial Results
GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2024. Recent Business Updates Therapy Selection Presented study results at the 2024 World Conference on Lung Cancer in September 2024.
Burning Rock Reports Third Quarter 2024 Financial Results
Neutral
GlobeNewsWire
2 weeks ago
Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024
GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 31, 2024 at 10:00 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No.
Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024
Neutral
GlobeNewsWire
2 months ago
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China
GUANGZHOU, China, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), an innovative company in the field of precision oncology, and Dizal, a global biopharmaceutical company focused on malignant tumors and immunological diseases, jointly announced that the companion diagnostic (CDx) for EGFR exon 20 insertion mutation (exon20ins) for sunvozertinib, developed through their collaboration, has been approved by the National Medical Products Administration (NMPA) of China. This marks the first co-developed NGS-based CDx for lung cancer approved by NMPA since the release of the CDx guideline in China.
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China
Neutral
GlobeNewsWire
2 months ago
Burning Rock Announces Changes to Management and Board of Directors
GUANGZHOU, China, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the resignation of Mr. Leo Li as a director from the Company's board of directors (the “Board”) and as the Company's chief financial officer, effective September 27, 2024.
Burning Rock Announces Changes to Management and Board of Directors
Neutral
GlobeNewsWire
4 months ago
Burning Rock Reports Second Quarter 2024 Financial Results
GUANGZHOU, China, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2024. Recent Business Updates Therapy Selection Presented study results on small-cell lung cancer and colorectal cancer at the ASCO in June 2024.
Burning Rock Reports Second Quarter 2024 Financial Results
Neutral
GlobeNewsWire
4 months ago
Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares
GUANGZHOU, China, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (the “Company” or “Burning Rock”) announces that, on August 19, 2024, it intends to submit requests (a) to the London Stock Exchange (the “LSE”), to cancel the admission to trading on the Main Market of its American Depositary Shares representing the class A ordinary shares of the Company (the “ADSs”), and (b) to the UK Financial Conduct Authority, to cancel the listing of the ADSs on the Official List. As a result of sustained low volume of trading and liquidity in the ADSs on the LSE, and taking into account the costs associated with maintaining such listing in place, the Company is seeking the delisting and cancellation of admission to trading of the ADSs from the LSE (the “Delisting”).
Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares
Neutral
GlobeNewsWire
6 months ago
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
GUANGZHOU, China, June 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received a notification letter from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“NASDAQ”) on May 30, 2024, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). As previously announced, on December 29, 2023, the Company was notified by NASDAQ that it was not in compliance with the Minimum Bid Price Requirement because the closing bid price for the Company's American depositary shares (the “ADSs”) was below the minimum bid price of $1.00 per share for 30 consecutive business days.
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
Neutral
GlobeNewsWire
6 months ago
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion diagnostic products in China, jointly developing NGS-based CDx for Bayer's growing portfolio of precision cancer therapies.
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
Neutral
Seeking Alpha
6 months ago
Burning Rock Biotech Limited (BNR) Q1 2024 Earnings Call Transcript
Burning Rock Biotech Limited (NASDAQ:BNR ) Q1 2023 Earnings Conference Call May 29, 2024 8:00 AM ET Company Participants Yusheng Han - Founder and Chief Executive Officer Leo Li - Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to the Burning Rock's 2024 First Quarter Earnings Conference Call.
Neutral
GlobeNewsWire
6 months ago
Burning Rock Reports First Quarter 2024 Financial Results
GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Detection and Clinical Application of Tumor DNA Methylation Markers (2024 Edition), showing an impressive performance of ELSA-seq using cfDNA in cancer detection and origin prediction.
Burning Rock Reports First Quarter 2024 Financial Results
Charts implemented using Lightweight Charts™